Italia markets closed

PHAXIAM Therapeutics S.A. (0QSS.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
2,2450-0,8250 (-26,87%)
Alla chiusura: 12:50PM BST
Schermo intero
Chiusura precedente3,0700
Aperto0,0000
Denaro0,0000 x 0
Domanda0,0000 x 0
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume1.260
Media Volume21
Capitalizzazione34,822M
Beta (mensile su 5 anni)1,79
Rapporto PE (ttm)N/D
EPS (ttm)-1,7330
Prossima data utili15 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM

    Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM Lyon (France) and Cambridge (MA, US), June 28, 2023 - Phaxiam Therapeutics (Nasdaq & Euronext: FR0011471135), announces change of the mnemonic code of its share from ERYP to PHXM, following the merger between ERYTECH and PHERECYDES. The change has been notified by Euronext and will be effective from June 29, 2023. Company name: Phaxiam TherapeuticsISIN code: FR0011471135Mnemonic: PHXMListing: Euronext Paris (Compar

  • GlobeNewswire

    Monthly information related to total number of voting rights and shares composing the share capital - June 26, 2023

    Monthly information related to total number of voting rights and shares composing the share capital _June 26, 2023. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2)

  • GlobeNewswire

    ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics

    ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics Merger approved with large majority by the shareholders of both companiesNew governance structure implementedAmbition to create a global leader in extended phage therapies to target antimicrobial resistant pathogenic bacteria Lyon (France) and Cambridge (MA, US), June 26, 2023 – ERYTECH (Nasdaq & Euronext: ERYP) and PHERECYDES announce merger and name change to PHAXIAM Therapeutics, a clinical-stage biopharmaceutical